Peripheral osteosarcoma

Summary

Peripheral osteosarcoma (MONDO:0002628) is a disease. A subtype of bone osteosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	peripheral osteosarcoma
Mondo ID	MONDO:0002628
DOID	DOID:3374
NCIT	C7134
UMLS	C1332591
MedGen	272379
GARD	0023196
Is cancer (heuristic)	no

Also known as: bone surface (peripheral) osteosarcoma · peripheral osteosarcoma · surface osteosarcoma

Disease family

This is a subtype of bone osteosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › osteosarcoma › bone osteosarcoma › peripheral osteosarcoma

Related subtypes (4): conventional osteosarcoma, metachronous osteosarcoma of the bone, telangiectatic osteogenic sarcoma, osteosarcoma arising in bone Paget disease

Subtypes (3): periosteal osteogenic sarcoma, high grade surface osteosarcoma, juxtacortical osteosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.